PeppiLibrary

Immune

Thymosin Alpha-1 peptide reference

Naturally occurring 28-AA thymic peptide. Approved abroad for hepatitis and immune support.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Thymosin Alpha-1 notes
Default dose label1.6 mg
Preferred routeSubQ
Frequency label2× weekly
Storage window7 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Approved in 35+ countries with extensive Phase 3 data; not US-approved

Prescription medication abroad; research chemical / off-label compound in US

Route map

How records are usually labeled

1 SubQ
2 IM

Rotate between abdomen and thigh.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C.
After mixUse immediately per label; off-label compounded vials may be refrigerated for 7–14 days.
Use-by cue7 days after mixing
Mixed vial window7 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 1.6 mg vial
Dose 1.6 mg
Route SubQ
Review 7d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Thymosin Alpha-1. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Thymosin Alpha-1 is a 28-amino-acid peptide derived from thymosin fraction 5, originally isolated from the thymus gland. It modulates T-cell maturation and function, enhances Th1 responses, and is approved in 35+ countries (not the US) for hepatitis B/C, immune restoration, and adjunctive cancer therapy. Used off-label in the US for chronic viral and immune-impaired conditions.

Also known as: Tα1, Zadaxin.

Chronic hepatitis B and C (approved abroad)Adjunctive cancer immunotherapyImmune restoration after illness or chemotherapyChronic viral infection support

Mechanism and timing snapshot

Promotes maturation and activity of T-cells; enhances Th1 cytokine production (IL-2, IFN-γ); upregulates dendritic cell function and toll-like receptor signalling.

Onset labelNot listed
Catalog onset field, when available.
Half-life label2 hr
Plasma half-life ~2 h; immunomodulatory effects persist days
Duration label72 hr
Catalog duration field, when available.
subQ High
IM High
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose1.6 mg
Catalog dose range800 mcg - 1.6 mg
Default routeSubQ
Frequency label2× weekly
Best time labelSame days each week, any time of day.
Food noteNone.

Catalog protocol note

1.6 mg subQ twice weekly for 6–12 months (label dose for hepatitis).

Routes and site notes

Available route labelsSubQ, IM
Preferred route labelSubQ
Common site labelsAbdomen, Thigh
Site rotation noteRotate between abdomen and thigh.

Chemistry

SequenceAc-SDAAVDTSSEITTKDLKEKKEVVEEAEN
Amino acids28
Molecular formulaC129H215N33O55
Molecular weight3108.3 Da

Vial, reconstitution, and storage

Supply formLyophilized powder (single-use vial in commercial Zadaxin)
Typical vial size1.6 mg
DiluentSterile water for injection (per label)
Diluent volume1 mL
Concentration note1.6 mg vial reconstituted with 1 mL → entire vial = full dose. Single-use only per label.
Before reconstitutionRefrigerate 2–8 °C.
After reconstitutionUse immediately per label; off-label compounded vials may be refrigerated for 7–14 days.
Reconstituted shelf life7 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Mild injection-site reactions
  • Generally extremely well-tolerated
  • Transient malaise
  • Mild flu-like symptoms early in use

Contraindications and warnings

  • Active autoimmune disease (theoretical — immune potentiation)
  • Active immunosuppressive therapy where immunosuppression is the goal
  • Not FDA-approved in the US.

Other considerations

  • Approved abroad with extensive clinical safety data — among the safest peptides in this catalog.
  • Not a stimulant of inflammation — it modulates rather than amplifies.

Evidence and regulatory context

Evidence levelApproved in 35+ countries with extensive Phase 3 data; not US-approved
FDA approvedNo
Regulatory statusPrescription medication abroad; research chemical / off-label compound in US
Prescription requiredYes
Approved countriesItaly, China, and 35+ others

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteActive immunosuppressive therapy where opposed to goal
Typical cycle label12–52
Typical break labelPer clinician
Cycle guidanceLong courses are typical for chronic indications; short courses for acute viral support.

Tracking tips

  • One of the most safety-validated peptides in this list — long international clinical track record.
  • Effects are cumulative — months not days.
  • If on immunosuppressants for autoimmune or transplant reasons, discuss with prescriber first.

References

Track it in Peppi

Keep Thymosin Alpha-1 records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Thymosin Alpha-1?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Thymosin Alpha-1?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Thymosin Alpha-1 records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026